Novel Adeno-Associated Virus Serotypes Efficiently Transduce Murine Photoreceptors
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Severe inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis, are caused by mutations in genes preferentially expressed in photoreceptors. While adeno-associated virus (AAV)-mediated gene transfer can correct retinal pigment epithelium (RPE) defects in animal models, approaches for the correction of photoreceptor-specific diseases are less efficient. We evaluated the ability of novel AAV serotypes (AAV2/7, AAV2/8, AAV2/9, AAV2rh.43, AAV2rh.64R1, and AAV2hu.29R) in combination with constitutive or photoreceptor-specific promoters to improve photoreceptor transduction, a limiting step in photoreceptor rescue. Based on a qualitative analysis, all AAV serotypes tested efficiently transduce the RPE as well as rod and cone photoreceptors after subretinal administration in mice. Interestingly, AAV2/9 efficiently transduces Müller cells. To compare photoreceptor transduction from different AAVs and promoters in both a qualitative and quantitative manner, we designed a strategy based on the use of a bicistronic construct expressing both enhanced green fluorescent protein and luciferase. We found that AAV2/8 and AAV2/7 mediate six- to eightfold higher levels of in vivo photoreceptor transduction than AAV2/5, considered so far the most efficient AAV serotype for photoreceptor targeting. In addition, following subretinal administration of AAV, the rhodopsin promoter allows significantly higher levels of photoreceptor expression than the other ubiquitous or photoreceptor-specific promoters tested. Finally, we show that AAV2/7, AAV2/8, and AAV2/9 outperform AAV2/5 following ex vivo transduction of retinal progenitor cells differentiated into photoreceptors. We conclude that AAV2/7 or AAV2/8 and the rhodopsin promoter provide the highest levels of photoreceptor transduction both in and ex vivo and that this may overcome the limitation to therapeutic success observed so far in models of inherited severe photoreceptor diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RPE cells can be targeted using AAV1, AAV4, or AAV6 vectors or with the engineered AAV2-7m8 vector, and photoreceptors and Müller glial cells are targeted by serotypes AAV2, AAV5, AAV6, AAV7, AAV8, and AAV9 as well as engineered AAV2-7m8 and AAV8BP2 vectors.56,112–116”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [114]
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“To evaluate the tropism of novel AAV serotypes following subretinal delivery to the adult murine retina and to determine if one is selective for photoreceptors, we generated AAV2/7 (25), AAV2/8 (25), AAV2/9 (23), AAV2/rh.”
MethodSelf-citationGene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Retinal Stem Cells in the Adult Mammalian Eye
Tropepe, V., Coles, B. L. K., Chiasson, B. J., Horsford, D. J., Elia, A. J., McInnes, R. R., & van der Kooy, D. (2000) · Science · doi:10.1126/science.287.5460.2032 · Cited by 1,081 · cited 1×
“This limitation hampers the possibility of genetically modifying retinal stem cells derived from the adult eye (54), which can be used as tools for cell therapy of retinal degenerations.”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 6×
“64 (23) and was optimized for production by”
BackgroundMethodInfluentialSelf-citationRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762 · cited 1×
“others have demonstrated that it is possible to tailor somatic transgene expression on distinct retinal cell types in the adult and fetal retina by exchanging the AAV capsids among the various AAV serotypes and that this may impact the therapeutic outcome in animal models of retinal diseases (7, 44, 51, 57).”
BackgroundNew recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Self-citationHermonat, P. L., & Muzyczka, N. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.20.6466 · Cited by 481 · cited 1×
“Since the generation of the first AAV vector (30, 53) (AAV2/2, in which the first number defines the vector genome and the second the capsid), dozens of AAV variants have been isolated, and some of them have been converted into gene delivery vehicles (11, 12, 23–25, 45).”
BackgroundAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Rutledge, E. A., Halbert, C. L., & Russell, D. W. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.309-319.1998 · Cited by 452
Research works printed but not linked: 3
- Dryja, T. 2001. Retinitis pigmentosa and stationary night blindness, p.5903 -5933. In C. R. Scriver, A. L. Beaudet, W. Sly, and D. M. Valle (ed.), The metabolic and molecular bases of inherited disease, 8th ed.,vol. IV. McGraw-Hill, New York, NY.
- Gregory-Evans, K., and R. G. Weleber. 2001. Retinitis pigmentosa and allied disorders in retina, p.362-460. In S. J. Ryan (ed.), Retinavol. 1, 3rd ed. Mosby, St. Louis, MO.
- 10.1128/mcb.4.10.2072-2081.1984 · doi:10.1128/mcb.4.10.2072-2081.1984 · Paper page
Cited by
Genetic Reactivation of Cone Photoreceptors Restores Visual Responses in Retinitis Pigmentosa
Busskamp, V., Duebel, J., Balya, D., Fradot, M., Viney, T. J., Siegert, S., Groner, A. C., Cabuy, E., Forster, V., Seeliger, M., et al. (2010) · Science · doi:10.1126/science.1190897 · Cited by 642
Ultra light-sensitive and fast neuronal activation with the Ca2+-permeable channelrhodopsin CatCh
Kleinlogel, S., Feldbauer, K., Dempski, R. E., Fotis, H., Wood, P. G., Bamann, C., & Bamberg, E. (2011) · Nature Neuroscience · doi:10.1038/nn.2776 · Cited by 476
Krol, J., Busskamp, V., Markiewicz, I., Stadler, M. B., Ribi, S., Richter, J., Duebel, J., Bicker, S., Fehling, H. J., Schübeler, D., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.039 · Cited by 470
Dias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., da Silva Cunha, A., Woo, S. J., & Kwon, Y. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 413
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
Inner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
“Animals were selected based on NAB to AAV8 and Anc80L65 with serum levels prior to injection below 1/4 titer.”
BackgroundSelf-citationBakondi, B., Lv, W., Lu, B., Jones, M. K., Tsai, Y., Kim, K. J., Levy, R., Akhtar, A. A., Breunig, J. J., Svendsen, C. N., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.220 · Cited by 296
Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292
“%) of the whole murine retina following subretinal administration of AAV (19) .”
BackgroundSelf-citationNrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice
Yu, W., Mookherjee, S., Chaitankar, V., Hiriyanna, S., Kim, J.-W., Brooks, M., Ataeijannati, Y., Sun, X., Dong, L., Li, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms14716 · Cited by 271
“These vectors were packaged into AAV type 8 (AAV8), a serotype transducing mouse photoreceptors efficiently 21 .”
InfluentialEffective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269
“The availability of AAV vector serotypes such as AAV2/8, which efficiently targets PR (Allocca et al, 2007; Natkunarajah et al, 2008; Auricchio, 2011; Mussolino et al, 2011; Vandenberghe et al, 2011) and RPE, further supports this approach.”
BackgroundMethodInfluentialSelf-citationIntracellular transport of recombinant adeno-associated virus vectors
Nonnenmacher, M., & Weber, T. (2012) · Gene Therapy · doi:10.1038/gt.2012.6 · Cited by 258
AAV cis -regulatory sequences are correlated with ocular toxicity
Xiong, W., Wu, D. M., Xue, Y., Wang, S. K., Chung, M. J., Ji, X., Rana, P., Zhao, S. R., Mai, S., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821000116 · Cited by 249
Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey
Vandenberghe, L. H., Bell, P., Maguire, A. M., Cearley, C. N., Xiao, R., Calcedo, R., Wang, L., Castle, M. J., Maguire, A. C., Grant, R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002103 · Cited by 242
“Other animal models have suggested that AAV8 has higher efficiency (13), and so to reduce animal use, we performed the AAV2 study after the AAV8 study in a dose de-escalating manner, and we terminated it at a dose of 10(10) genome copies per eye because this dose yielded expression levels quantitatively comparable to…”
ResultSelf-citationJüttner, J., Szabo, A., Gross-Scherf, B., Morikawa, R. K., Rompani, S. B., Hantz, P., Szikra, T., Esposti, F., Cowan, C. S., Bharioke, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0431-2 · Cited by 218
“, 2007), AAV9 (Allocca et al., 2007; Lebherz et al., 2008), and AAV8BP2 (Cronin et al.”
MethodInfluentialRecombinant Adeno-associated Virus Transduction and Integration
Schultz, B. R., & Chamberlain, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.103 · Cited by 215
Pharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213
“(64,80), while cone photoreceptor–specific expression can be achieved using cone arrestin, blue opsin, or red/green opsin”
Backgroundden Hollander, A. I., Black, A., Bennett, J., & Cremers, F. P. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42258 · Cited by 207
van Wyk, M., Pielecka-Fortuna, J., Löwel, S., & Kleinlogel, S. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002143 · Cited by 208
“1-Rho-EGFP vector (kind gift from A. Auricchio) [73], using an In-Fusion 2.0 homologous recombination Kit (Clontech).”
InfluentialMacé, E., Caplette, R., Marre, O., Sengupta, A., Chaffiol, A., Barbe, P., Desrosiers, M., Bamberg, E., Sahel, J.-A., Picaud, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.154 · Cited by 197
“Natural AAVs have been shown to transduce effectively retinal ganglion cells following intravitreal injection 15,16 , and photoreceptors using subretinal injection in normal retinas 17 .”
InfluentialMichalakis, S., Mühlfriedel, R., Tanimoto, N., Krishnamoorthy, V., Koch, S., Fischer, M. D., Becirovic, E., Bai, L., Huber, G., Beck, S. C., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.149 · Cited by 185
Vector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
“AAV2/5, 2/7, 2/8 and 2/9 have all been demonstrated to efficiently transduce PR, in addition to RPE (Allocca et al., 2007; Auricchio et al., 2001; Lebherz et al., 2008; Lotery et al., 2003), with AAV2/8 being the most efficient serotype in mice (Allocca et al.”
BackgroundInfluentialSelf-citationMolecular evolution of adeno-associated virus for enhanced glial gene delivery
Koerber, J. T., Klimczak, R., Jang, J.-H., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · Molecular Therapy · doi:10.1038/mt.2009.184 · Cited by 181
Carvalho, L. S., Xu, J., Pearson, R. A., Smith, A. J., Bainbridge, J. W., Morris, L. M., Fliesler, S. J., Ding, X.-Q., & Ali, R. R. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr218 · Cited by 173
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors
Kay, C. N., Ryals, R. C., Aslanidi, G. V., Min, S. H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D., Ayala, A. E., Van Vliet, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062097 · Cited by 168
“Several serotypes have been used to successfully target transgene to PRs following subretinal injection, including AAV2, AAV5 and AAV8 with all three demonstrating efficacy in proof of concept experiments across multiple species (mouse, rat, dog, pig and non-human primate) [8–21].”
BackgroundMethodGene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Natkunarajah, M., Trittibach, P., McIntosh, J., Duran, Y., Barker, S. E., Smith, A. J., Nathwani, A. C., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303074 · Cited by 138
Collin, R. W., den Hollander, A. I., van der Velde-Visser, S. D., Bennicelli, J., Bennett, J., & Cremers, F. P. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.3 · Cited by 137
Novel adeno-associated viral vectors for retinal gene therapy.
Vandenberghe, L. H., & Auricchio, A. (2012) · Gene Therapy · doi:10.1038/gt.2011.151 · Cited by 131
Self-citationAdult Human Müller Glia Cells Are a Highly Efficient Source of Rod Photoreceptors
Giannelli, S. G., Demontis, G. C., Pertile, G., Rama, P., & Broccoli, V. (2011) · Stem Cells · doi:10.1002/stem.579 · Cited by 146
Triple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128
Self-citationSun, X., Pawlyk, B., Xu, X., Liu, X., Bulgakov, O. V., Adamian, M., Sandberg, M. A., Khani, S. C., Tan, M.-H., Smith, A. J., et al. (2010) · Gene Therapy · doi:10.1038/gt.2009.104 · Cited by 123
RetractedMassively parallel cis-regulatory analysis in the mammalian central nervous system
Shen, S. Q., Myers, C. A., Hughes, A. E. O., Byrne, L. C., Flannery, J. G., & Corbo, J. C. (2016) · Genome Research · doi:10.1101/gr.193789.115 · Cited by 126
AAV-mediated gene therapy for retinal disorders: from mouse to man
Buch, P. K., Bainbridge, J. W., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.66 · Cited by 134
Tan, M. H., Smith, A. J., Pawlyk, B., Xu, X., Liu, X., Bainbridge, J. B., Basche, M., McIntosh, J., Tran, H. V., Nathwani, A., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp133 · Cited by 119
“Compared with AAV2/2 and AAV2/5, AAV2/8 is much more efficient at transducing the retina (17) (36).”
BackgroundBinley, K., Widdowson, P., Loader, J., Kelleher, M., Iqball, S., Ferrige, G., de Belin, J., Carlucci, M., Angell-Manning, D., Hurst, F., et al. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11871 · Cited by 115
Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward
Bennett, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.008 · Cited by 109
Nanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107
O’Carroll, S. J., Cook, W. H., & Young, D. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.618020 · Cited by 107
Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors
Colella, P., Trapani, I., Cesi, G., Sommella, A., Manfredi, A., Puppo, A., Iodice, C., Rossi, S., Simonelli, F., Giunti, M., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.8 · Cited by 103
Self-citationAAV-mediated photoreceptor transduction of the pig cone-enriched retina
Mussolino, C., della Corte, M., Rossi, S., Viola, F., Di Vicino, U., Marrocco, E., Neglia, S., Doria, M., Testa, F., Giovannoni, R., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.3 · Cited by 102
Self-citationMeola, N., Pizzo, M., Alfano, G., Surace, E. M., & Banfi, S. (2011) · RNA · doi:10.1261/rna.029454.111 · Cited by 105
“(Allocca et al. 2007), previously linearized with NheI to obtain”
MethodSelf-citationAAV9 targets cone photoreceptors in the nonhuman primate retina
Vandenberghe, L. H., Bell, P., Maguire, A. M., Xiao, R., Hopkins, T. B., Grant, R., Bennett, J., & Wilson, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053463 · Cited by 97
“effective than AAV5 in PR targeting in mouse [17,18].”
BackgroundSelf-citationGene therapy restores vision in rd1 mice after removal of a confounding mutation in Gpr179
Nishiguchi, K. M., Carvalho, L. S., Rizzi, M., Powell, K., Holthaus, S.-M. K., Azam, S. A., Duran, Y., Ribeiro, J., Luhmann, U. F. O., Bainbridge, J. W. B., et al. (2015) · Nature Communications · doi:10.1038/ncomms7006 · Cited by 94
Beltran, W. A., Boye, S. L., Boye, S. E., Chiodo, V. A., Lewin, A. S., Hauswirth, W. W., & Aguirre, G. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.56 · Cited by 96
Duebel, J., Marazova, K., & Sahel, J. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000140 · Cited by 123
“Sub-retinally delivered naturally occurring AAV serotypes are able to deliver genes to diverse cell types including glia, epithelium, and many types of neurons [44].”
Dosage thresholds and influence of transgene cassette in adeno-associated virus–related toxicity
Khabou, H., Cordeau, C., Pacot, L., Fisson, S., & Dalkara, D. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.144 · Cited by 93
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“Mouse RHO 1400 Rod PRCs [104] Human RHO (rhodopsin) 800 Rod PRCs [105] Human RHO 520 Rod- PRCs [24]”
BackgroundGuimaraes, T. A. C. D., Georgiou, M., Bainbridge, J. W. B., & Michaelides, M. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316195 · Cited by 91
Beltran, W. A., Cideciyan, A. V., Iwabe, S., Swider, M., Kosyk, M. S., McDaid, K., Martynyuk, I., Ying, G.-S., Shaffer, J., Deng, W.-T., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509914112 · Cited by 89
Berger, A., Lorain, S., Joséphine, C., Desrosiers, M., Peccate, C., Voit, T., Garcia, L., Sahel, J.-A., & Bemelmans, A.-P. (2015) · Molecular Therapy · doi:10.1038/mt.2015.11 · Cited by 92
AAV-Mediated Gene Delivery to 3D Retinal Organoids Derived from Human Induced Pluripotent Stem Cells
Garita-Hernandez, M., Routet, F., Guibbal, L., Khabou, H., Toualbi, L., Riancho, L., Reichman, S., Duebel, J., Sahel, J.-A., Goureau, O., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030994 · Cited by 82
“Similarly, rAAV9 gave rise to poor transduction in our retinal organoids despite being highly successful in targeting cones in mice and nonhuman primates [25,30].”
BackgroundAdvances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
“AAV2 and lentiviral vectors, though excellent vectors for transducing the RPE, were found to be inefficient in transducing photoreceptor cells.(42,43) However, several novel AAV serotypes have been identified and characterized.”
BackgroundProspects for retinal gene replacement therapy
Smith, A. J., Bainbridge, J. W., & Ali, R. R. (2009) · Trends in Genetics · doi:10.1016/j.tig.2009.02.003 · Cited by 100
Kleinlogel, S., Terpitz, U., Legrum, B., Gökbuget, D., Boyden, E. S., Bamann, C., Wood, P. G., & Bamberg, E. (2011) · Nature Methods · doi:10.1038/nmeth.1766 · Cited by 95
“The PCR-amplified LTR promoter sequence was cut by NheI and PstI and inserted into pAAV2-Rho-EGFP 31”
MethodGene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
“Subretinal injections of rAAV2/1 and rAAV2/6 were shown to transduce only RPE cells(23) as was rAAV2/ 4(24) whilst rAAV2/2, rAAV2/5, rAAV2/7, rAAV2/8, and rAAV2/9 all show RPE and photoreceptor transduction in mice.(25) Expression onset of the transgene varies between the serotypes with rAAV2/2 showing later onset of…”
MethodPawlyk, B. S., Bulgakov, O. V., Sun, X., Adamian, M., Shu, X., Smith, A. J., Berson, E. L., Ali, R. R., Khani, S., Wright, A. F., et al. (2016) · Gene Therapy · doi:10.1038/gt.2015.93 · Cited by 77
Pawlyk, B. S., Bulgakov, O. V., Liu, X., Xu, X., Adamian, M., Sun, X., Khani, S. C., Berson, E. L., Sandberg, M. A., & Li, T. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.218 · Cited by 79
“…to package the therapeutic gene construct into AAV2/8 to take advantage of the known benefits of this version of AAV vector, such as faster onset of transgene expression and higher expression levels in photoreceptor cells (G.S. Yang et al. , 2002; Allocca et al. , 2007; Natkunarajah et al. , 2008).”
Stieger, K., Colle, M.-A., Dubreil, L., Mendes-Madeira, A., Weber, M., Le Meur, G., Deschamps, J. Y., Provost, N., Nivard, D., Cherel, Y., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.41 · Cited by 75
Achberger, K., Cipriano, M., Duechs, M. J., Schön, C., Michelfelder, S., Stierstorfer, B., Lamla, T., Kauschke, S. G., Chuchuy, J., Roosz, J., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.08.008 · Cited by 81
Mussolino, C., Sanges, D., Marrocco, E., Bonetti, C., Di Vicino, U., Marigo, V., Auricchio, A., Meroni, G., & Surace, E. M. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201000119 · Cited by 74
“We generated an AAV2/8 vector, as this is currently considered to be most efficient AAV delivery vehicle for photoreceptor gene transfer (Allocca et al, 2007; Lebherz et al, 2008; Natkunarajah et al, 2008; Stieger et al, 2008).”
BackgroundMethodSelf-citationCereso, N., Pequignot, M. O., Robert, L., Becker, F., De Luca, V., Nabholz, N., Rigau, V., De Vos, J., Hamel, C. P., & Kalatzis, V. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.11 · Cited by 72
Mihelec, M., Pearson, R. A., Robbie, S. J., Buch, P. K., Azam, S. A., Bainbridge, J. W. B., Smith, A. J., & Ali, R. R. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.069 · Cited by 72
“In this study we used an rAAV2/8 serotype as previously we and other groups have demonstrated more efficient transduction of photoreceptor cells as well as higher levels of transgene expression after the use of this serotype compared with AAV2/5 (Yang et al., 2002; Allocca et al., 2007; Natkunarajah et al., 2008).”
BackgroundMethodInfluentialVandenberghe, L. H., Breous, E., Nam, H.-J., Gao, G., Xiao, R., Sandhu, A., Johnston, J., Debyser, Z., Agbandje-McKenna, M., & Wilson, J. M. (2009) · Gene Therapy · doi:10.1038/gt.2009.101 · Cited by 72
Self-citationKhabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A., Sahel, J., & Dalkara, D. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26031 · Cited by 71
“AAV2, -5, -7, -8, -9 have been successful in gene transfer to photoreceptors when delivered into the subretinal space (Allocca et al., 2007; Auricchio et al., 2001; Mowat et al., 2014; Natkunarajah et al., 2008).”
BackgroundMethodOcular gene therapy: current progress and future prospects
Colella, P., Cotugno, G., & Auricchio, A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.003 · Cited by 78
“rAAV2/9 vectors, in addition to PRs, efficiently transduce Mu¨ller cells [ 5 ], and transduction of ganglion cells can be achieved by intravitreal injection of either rAAV2/2 or rAAV2/8 vectors [6].”
BackgroundSelf-citationA long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration
Wu, Z., Hiriyanna, S., Qian, H., Mookherjee, S., Campos, M. M., Gao, C., Fariss, R., Sieving, P. A., Li, T., Colosi, P., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv134 · Cited by 69
Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 78
“The serotypes AAV2/5, 2/7, 2/8 and 2/9 readily transduce photoreceptors [20,39,41].”
BackgroundEmerging approaches for restoration of hearing and vision
Kleinlogel, S., Vogl, C., Jeschke, M., Neef, J., & Moser, T. (2020) · Physiological Reviews · doi:10.1152/physrev.00035.2019 · Cited by 92
Vectors and Gene Delivery to the Retina
Planul, A., & Dalkara, D. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061413 · Cited by 67
“AAV serotypes 2, 5, 6, 7, 8, and 9 and engineered variants AAV2–7m8 and AAV8BP2 all allow efficient photoreceptor gene delivery (Allocca et al. 2007; Boye et al. 2012; Vandenberghe et al. 2011, 2013).”
BackgroundCarvalho, L. S., Xiao, R., Wassmer, S. J., Langsdorf, A., Zinn, E., Pacouret, S., Shah, S., Comander, J. I., Kim, L. A., Lim, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.154 · Cited by 63
“These results demonstrate a broader potential for Anc80 to target INL neurons and glia via subretinal administration when compared with AAV8, which has only been shown to occasionally transduce ganglion cells and Muller glia.(22,23) Furthermore, Anc80L65 and Anc80L27 variants were shown to have a much faster onset of…”
ResultSelf-citationGargiulo, A., Bonetti, C., Montefusco, S., Neglia, S., Di Vicino, U., Marrocco, E., Corte, M. D., Domenici, L., Auricchio, A., & Surace, E. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.112 · Cited by 61
Self-citationMicroRNA-Restricted Transgene Expression in the Retina
Karali, M., Manfredi, A., Puppo, A., Marrocco, E., Gargiulo, A., Allocca, M., Corte, M. D., Rossi, S., Giunti, M., Bacci, M. L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022166 · Cited by 60
“For instance, the promoter of Rhodopsin - a gene strongly and specifically expressed in rod PRs- induces aberrant reporter expression also in cones [27,44].”
BackgroundInfluentialSelf-citationHan, I. C., Cheng, J. L., Burnight, E. R., Ralston, C. L., Fick, J. L., Thomsen, G. J., Tovar, E. F., Russell, S. R., Sohn, E. H., Mullins, R. F., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.043 · Cited by 60
Watanabe, S., Sanuki, R., Ueno, S., Koyasu, T., Hasegawa, T., & Furukawa, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054146 · Cited by 59
“H) Infection efficiencies of AAV2/1- (B), AAV2/2- (C), AAV2/5- (D), AAV2/8- (E), AAV2/9- (F), AAV2/10- (G), and AAV2/11- (H), CAG-mCherry.”
InfluentialWoodard, K. T., Liang, K. J., Bennett, W. C., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.01568-16 · Cited by 59
Retinal transduction profiles by high-capacity viral vectors
Puppo, A., Cesi, G., Marrocco, E., Piccolo, P., Jacca, S., Shayakhmetov, D. M., Parks, R. J., Davidson, B. L., Colloca, S., Brunetti-Pierri, N., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.57 · Cited by 56
Self-citationGene supplementation therapy for recessive forms of inherited retinal dystrophies
Smith, A. J., Bainbridge, J. W., & Ali, R. R. (2011) · Gene Therapy · doi:10.1038/gt.2011.161 · Cited by 66
Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa
Wert, K. J., Davis, R. J., Sancho-Pelluz, J., Nishina, P. M., & Tsang, S. H. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds466 · Cited by 55
Askou, A. L., Pournaras, J. C., Pihlmann, M., Svalgaard, J. D., Arsenijevic, Y., Kostic, C., Bek, T., Dagnæs‐Hansen, F., Mikkelsen, J. G., Jensen, T. G., et al. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2678 · Cited by 55
“of RPE cells by AAV serotype 8 following subretinal injection is in accordance with observations from other groups studying the behavior of the AAV serotype 8 vector with regard to intraocular delivery [37,38].”
ResultGene-based therapies for dominantly inherited retinopathies
Farrar, G. J., Millington‐Ward, S., Chadderton, N., Humphries, P., & Kenna, P. F. (2011) · Gene Therapy · doi:10.1038/gt.2011.172 · Cited by 62
Hasan, N., Pangeni, G., Cobb, C. A., Ray, T. A., Nettesheim, E. R., Ertel, K. J., Lipinski, D. M., McCall, M. A., & Gregg, R. G. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.056 · Cited by 57
The Future Looks Brighter After 25 Years of Retinal Gene Therapy
Auricchio, A., Smith, A. J., & Ali, R. R. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.164 · Cited by 52
Self-citationGene Therapy of Inherited Retinopathies: A Long and Successful Road from Viral Vectors to Patients
Colella, P., & Auricchio, A. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.123 · Cited by 50
“…2011); (ii) the availability of AAV2/7, 2/9, and 2/5 as alternatives to AAV2/8 for PR transduction (Auricchio et al., 2001; Lotery et al., 2003; Allocca et al., 2007; Mussolino et al., 2011a); and (iii) the generation of tyrosine-mutated AAV capsids (Zhong et al., 2008b) that avoid targeting…”
BackgroundSelf-citationUpdate on viral gene therapy clinical trials for retinal diseases
Cheng, S.-Y., & Punzo, C. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.159 · Cited by 49
Karali, M., Guadagnino, I., Marrocco, E., De Cegli, R., Carissimo, A., Pizzo, M., Casarosa, S., Conte, I., Surace, E. M., & Banfi, S. (2020) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.11.005 · Cited by 48
“The AAV2/8 serotype is reported to transduce the RPE and PRs efficiently upon subretinal administration in several species, including mice.(15) Vectors expressing either the miR-204 precursor bearing a mutated seed sequence (AAV.”
BackgroundSelf-citationAllele-specific editing ameliorates dominant retinitis pigmentosa in a transgenic mouse model
Patrizi, C., Llado, M., Benati, D., Iodice, C., Marrocco, E., Guarascio, R., Surace, E. M., Cheetham, M. E., Auricchio, A., & Recchia, A. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.01.006 · Cited by 47
Self-citationTherapeutic homology-independent targeted integration in retina and liver
Tornabene, P., Ferla, R., Llado-Santaeularia, M., Centrulo, M., Dell’Anno, M., Esposito, F., Marrocco, E., Pone, E., Minopoli, R., Iodice, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29550-8 · Cited by 44
Self-citationOcular delivery of CRISPR/Cas genome editing components for treatment of eye diseases
Yu, W., & Wu, Z. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.011 · Cited by 50
Mookherjee, S., Hiriyanna, S., Kaneshiro, K., Li, L., Li, Y., Li, W., Qian, H., Li, T., Khanna, H., Colosi, P., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv354 · Cited by 43
“The construct was packaged into AAV8, one of the naturally occurring AAV serotypes that transduce photoreceptors of mouse and non-human primate most efficiently (37,39,40), and was designated as AAV8-scRK-hRP2 vector.”
BackgroundSpampanato, C., De Leonibus, E., Dama, P., Gargiulo, A., Fraldi, A., Sorrentino, N. C., Russo, F., Nusco, E., Auricchio, A., Surace, E. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.299 · Cited by 44
Self-citationTesta, F., Surace, E. M., Rossi, S., Marrocco, E., Gargiulo, A., Di Iorio, V., Ziviello, C., Nesti, A., Fecarotta, S., Bacci, M. L., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6543 · Cited by 44
“We generated AAV vectors encoding AIPL1 based on serotype 8 (AAV2/8-RHO-hAIPL1 and AAV2/8-CMVhAIPL1), which are currently considered the most efficient for photoreceptors transduction.(24,30) We injected Aipl1 / mice subretinally with AAV vectors from postnatal day (P)4 to P8 before degeneration occurs.”
MethodSelf-citationBarriers for retinal gene therapy: separating fact from fiction.
Kumar-Singh, R. (2008) · Vision Research · doi:10.1016/j.visres.2008.05.005 · Cited by 43
“For example, AAV serotype 2 (AAV2) can be pseudotyped with AAV8 coat proteins to enhance photoreceptor tropism in adult mice (Allocca et al., 2007).”
BackgroundAllocca, M., Manfredi, A., Iodice, C., Di Vicino, U., & Auricchio, A. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6269 · Cited by 42
“1-RHO-EGFP digested with NheI and NotI.32 The AAV2/8 and -2/5 vectors were produced by the TIGEM Vector Core by triple transfection of 293 cells followed by two rounds of CsCl2 purification.”
MethodSelf-citationCombined Rod and Cone Transduction by Adeno-Associated Virus 2/8
Manfredi, A., Marrocco, E., Puppo, A., Cesi, G., Sommella, A., Della Corte, M., Rossi, S., Giunti, M., Craft, C. M., Bacci, M. L., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.154 · Cited by 43
“…an intraperitoneal injection of avertin (1.25% w/v of 2,2,2- tribromoethanol and 2.5% v/v of 2-methyl-2-Butanol; Sigma– Aldrich, St. Louis, MO) at 2 ml/100 g of body weight, and viral vectors were delivered via a transscleral–transchoroidal approach, as previously described (Allocca et al., 2007).”
BackgroundMethodResultInfluentialSelf-citationGenetics, pathogenesis and therapeutic developments for Usher syndrome type 2
Stemerdink, M., García‐Bohórquez, B., Schellens, R. T. W., García‐García, G., van Wijk, E., & Millán, J. M. (2021) · Human Genetics · doi:10.1007/s00439-021-02324-w · Cited by 49
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41
(2011) · PubMed Central · Cited by 41
Gene Therapy of ABCA4-Associated Diseases
Auricchio, A., Trapani, I., & Allikmets, R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017301 · Cited by 41
“AAV2/5, 2/7, 2/8, and 2/9 vectors have all efficiently transduced PRs, in addition to RPE (Auricchio et al. 2001; Lotery et al. 2003; Allocca et al. 2007), with the AAV2/8 being the most efficient serotype in mice (Auricchio et al. 2001; Lotery et al. 2003; Allocca et al. 2007), pigs (Mussolino et…”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo, M., Vandenberghe, L. H., Wilson, J. M., Marigo, V., Surace, E. M., & Auricchio, A.
- Affiliations
- European School of Molecular Medicine (IT)
- Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy
- University of Modena and Reggio Emilia (IT)
- Telethon Institute Of Genetics And Medicine (IT)
- University of Pennsylvania (US)
- Federico II University Hospital (IT)
- ORCID
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2007-10-15
- Volume
- 81
- Issue
- 20
- Pages
- 11372-11380
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC2045569
- OpenAlex
- W2155190242
- Cited by
- 246
- References
- 59
- Citations by year
- 2026: 11 · 2025: 9 · 2024: 6 · 2023: 10 · 2022: 11 · 2021: 14 · 2020: 10 · 2019: 14 · 2018: 12 · 2017: 16 · 2016: 7 · 2015: 30 · 2014: 11 · 2013: 16 · 2012: 13
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Funders
- National Eye Institute (R01EY015136)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus serotypes, phototransduction, AAV2/8, AAV2/9, rhodopsin promoter, retinitis pigmentosa, Leber congenital amaurosis, inherited retinal disease, subretinal gene therapy, Müller cells, retinal progenitor cells, AAV2/5, luciferase reporter
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Photoreceptor Cells, Promoter Regions, Genetic, Retina, Rhodopsin, Serotyping, Transduction, Genetic, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.